Mobile Menu

Venture News

Years

Categories

Media Inquiries

Drew Hoffman

dhoffman@echo.global

and/or marketing@echo.global

405.279.6664

January 30, 2023

Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application

Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.

Read More

June 7, 2021

Oklahoma City Launches New Prairie Surf Studios As State Boosts Production Incentives

Prairie Surf Studios has officially launched in downtown Oklahoma City in a converted convention center with five new soundstages and over 1.3 million square feet of production support space.

Read More

July 21, 2021

Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics

Alloy Therapeutics and Echo Investment Capital today announced the formation of Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact. Wheeler’s comprehensive discovery-to-IND programs are designed to provide emerging biopharma companies a faster and more predictable path to the clinic.

Read More

October 21, 2021

Zeno Technologies Unveils a New Platform to Help Energy Companies Thrive in the Production Era

Zeno Technologies today unveiled a new cloud-based platform to help energy companies, investors and partners adapt and thrive in the face of new market realities in the Production Era. The energy industry is fundamentally different than it was just a few short years ago, and today’s energy-focused organizations need a set of modern tools to unlock data to inform smarter, faster business decisions. Zeno’s new Energy Operating System provides the clarity to understand and improve business performance, and the insight to decisively assess and pursue new investment opportunities.

Read More

November 16, 2021

Deka Biosciences Raises USD 20 Million in Series A Financing

Maryland-based biotech company Deka Biosciences ("Deka") today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led by Leaps by Bayer, the impact investment arm of Bayer AG, and new investor Lumira Ventures. Additional investors include O-Bio (Echo Investment Capital), Viva BioInnovator, and Alexandria Venture Investments.

Read More

December 7, 2021

Zeno Technologies Creates Pioneer Customer Program for Energy Businesses Ready to Run on Real-Time Insights

Zeno Technologies today unveiled its new Pioneer customer program to partner with trailblazing organizations to help build a more trusted future for the energy industry by enabling smarter decisions through data-driven business insight. The program – specially designed for businesses eager to embrace new technologies – will offer up to 10 companies a curated package of Pioneer benefits, including early access to new product features, enhanced customer support, C-level engagement with Zeno’s leadership team, direct input into product development, and special networking opportunities for virtual & in-person collaboration with fellow energy industry Pioneers.

Read More

January 4, 2022

Wheeler Bio Announces $14M Seed Round To Expand Access To Portable CMC™

Wheeler Bio, a biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact, announced today the closing of a $14M Seed financing round. The round was co-led by Echo Investment Capital and Alloy Therapeutics, with participation from Floating Point and Presbyterian Health Foundation.

Read More

July 19, 2022

Deka Biosciences Breaks Ground on New Facility

Deka Biosciences announced today that it is breaking ground on a 14,000 square foot office and lab which will house a state of the art Research and Development, Process Development, and Manufacturing facility to further develop their novel cytokine therapies. This will be the first facility to house a dual targeted cytokine development lab in the DC/Maryland/Virginia region and the only company in the US developing a therapeutic of its kind. The new headquarters will be located at 20380 Seneca Meadows Parkway in Germantown, Maryland and Deka anticipates the move to be completed in the first quarter of 2023.

Read More

August 10, 2022

Zeno Celebrates Key Milestones in Customer Acquisition, Product Growth

Zeno Technologies, a pioneer in helping businesses master the financial performance of their energy assets, has achieved significant traction following the company’s public launch in October 2021. In just nine months since emerging from stealth, Zeno won key client engagements and expanded its product offering to help energy businesses exert better capital discipline to deliver predictable returns to their investors.

Read More

August 30, 2022

Zeno Technologies Helps Oil Companies Make Smarter Decisions

After noticing a relative lack of software investment in the oil and gas industry, Zeno Technologies has developed a data aggregation and analytics platform. It helps oil and gas companies analyze multiple operational scenarios through financial modeling with the goal of providing consistent returns to investors.

Read More

September 8, 2022

Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations

Deka Biosciences ("Deka"), a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases, announced today the appointment of Charlotte Moser, MD, PhD, MSc, MBA as Chief Medical Officer (CMO) and Deb Kientop, MBA as Vice President, Clinical Operations.

Read More

October 4, 2022

Wheeler Bio Announces Series A Financing Round Led by Echo, Charles River Laboratories

OKLAHOMA CITY – Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in small batch clinical production of biologics and GMP-grade reagents using their open-source platform, Portable CMC™, today announced the first closing of their Series A financing round. The round was co-led by Charles River Laboratories and Echo Investment Capital with participation from ATUM, Floating Point Advisors, Plains Venture Partners (a subsidiary of i2E), and Pine Ridge Ventures.

Read More

October 21, 2022

Zeno Technologies Unveils a New Platform to Help Energy Companies Thrive in the Production Era

Zeno Technologies today unveiled a new cloud-based platform to help energy companies, investors and partners adapt and thrive in the face of new market realities in the Production Era. The energy industry is fundamentally different than it was just a few short years ago, and today’s energy-focused organizations need a set of modern tools to unlock data to inform smarter, faster business decisions. Zeno’s new Energy Operating System provides the clarity to understand and improve business performance, and the insight to decisively assess and pursue new investment opportunities.

Read More

November 1, 2022

Prairie Surf Media Completes Production of First Season of ‘Tulsa King’

OKLAHOMA CITY – Echo-backed global production company Prairie Surf Media recently completed work on Season 1 of “Tulsa King,” a crime drama starring Sylvester Stallone. The Paramount+ drama series premiers Nov. 13. Prairie Surf Studios, headquartered in Oklahoma City, features 1.3 million square feet, five soundstages, and access to the world’s most diverse ecoregions. Check out the must-see “Tulsa King” series trailer

Read More

November 3, 2022

Wheeler Bio, CRB announce kickoff of new Oklahoma City manufacturing facility supporting production of life-saving therapies

Contract Development and Manufacturing Organization (CDMO) Wheeler Bio and CRB – a leading global provider of sustainable engineering, architectural, construction and consulting services to the life sciences industry – today announced the start of construction on a GMP drug substance facility that will support innovators seeking agile, small batch manufacturing services for their clinical trial materials (CTM).

Read More

Let’s build something great together.